Alector (ALEC) Expected to Post Earnings on Thursday

Alector (NASDAQ:ALEC) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $2.38 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. The firm had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million. On average, analysts expect Alector to post ($0.47) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Alector Price Performance

Shares of ALEC opened at $2.25 on Thursday. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80. The stock’s 50 day moving average is $2.09 and its two-hundred day moving average is $2.02. Alector has a twelve month low of $1.09 and a twelve month high of $2.76. The firm has a market capitalization of $251.24 million, a PE ratio of -2.05 and a beta of 0.62.

Insider Transactions at Alector

In other Alector news, CFO Neil Berkley sold 29,251 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer directly owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Arnon Rosenthal sold 72,606 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $193,131.96. Following the completion of the transaction, the chief executive officer directly owned 2,294,600 shares of the company’s stock, valued at approximately $6,103,636. This trade represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 111,303 shares of company stock worth $295,633. 8.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. HC Wainwright lifted their price target on Alector from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Morgan Stanley upped their price objective on Alector from $2.00 to $3.00 and gave the stock an “underweight” rating in a report on Tuesday, October 6th. Finally, UBS Group reiterated a “neutral” rating and issued a $1.50 price objective on shares of Alector in a research report on Tuesday, October 6th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.62.

Alector Company Profile

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.